Correlation of prostate-specific antigen and technetium-99m HMDP bone imaging
| Autor: | Sylvia Magoun, Judy Collins, Wei-Jen Shih, Ryo Uy, Becky Wierzbinski, Pearson Tc |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Male
Pathology medicine.medical_specialty Bone disease Urology Bone Neoplasms Technetium Tc 99m Medronate Scintigraphy Metastasis Prostate Antigens Neoplasm medicine Carcinoma Biomarkers Tumor Humans Radiology Nuclear Medicine and imaging Prospective Studies Radionuclide Imaging Aged medicine.diagnostic_test Epithelioma business.industry Cancer Prostatic Neoplasms General Medicine Middle Aged Prostate-Specific Antigen medicine.disease Prostate-specific antigen medicine.anatomical_structure business |
| Zdroj: | Clinical nuclear medicine. 14(10) |
| ISSN: | 0363-9762 |
| Popis: | For an evaluation of the clinical utility of prostate-specific antigen (PSA), 32 prostatic carcinoma patients (ages 54-76) and 13 nonprostatic carcinoma patients (ages 60-70) underwent PSA measurements and bone imaging. At the time of bone imaging, each patient's PSA value was measured by a monoclonal immunoradiometric assay. All 13 nonprostatic carcinoma patients (11 bronchogenic, 1 colon, and 1 urinary bladder) gave normal PSA values, although 6 had metastatic bone disease. The 32 prostatic cancer patients were divided into 2 groups of 16 each; PSA levels in Group 1 were abnormal (greater than or equal to ng/ml): PSA levels in Group 2 were normal (less than 4 ng/ml). In Group 1, bone images of 14 patients showed bone metastases; 6 of the 14 showed progression of metastases in a 6- to 12-month period. Two patients in Group 1 were negative for skeletal metastases. Twelve patients in Group 2 were negative for skeletal metastases; bone imaging in 1 showed regression of skeletal metastases; and 3 patients had unchanged bone lesion(s). The data indicate that PSA measurements may enhance bone imaging interpretation and provide valuable clinical monitoring of prostatic carcinoma. In the case of a patient with positive bone imaging and an unknown primary, PSA measurements may definitively determine if metastases originated from prostatic carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|